Nanotechnology Perceptions
ISSN 1660-6795
www.nano-ntp.com

Targeted Drug Delivery Systems In Nanomedicine: Enhancing Therapeutic Efficacy In Oncology And Beyond

Aliu Olalekan Olatunji[1*], Tariq Rafique[2], Hira Aslam[3], Naseem Akhter[4], Baneen C. Gabble[5], Sri Pranita Cherukuri[6], Tufail Ahmad[7], Asaad Babker[8]

*[*1]Doctor, Department of Medical Microbiology and Immunology, University of Toledo, USA, Email: aliu_my2004@yahoo.com*
[2]Assistant Professor, DadaBhoy Institute of Higher Education, Karachi, Pakistan Email: dr.tariq1106@gmail.com
[3]Pharmacy Student, Department of Pharmacy, University of Sargodha, Pakistan Email: hirahassan1000@gmail.com
[4]Assistant Editor, Research journal of Innovative Ideas and Thoughts dr.naseemrana786@gmaail.com
[5]Medical Laboratory Technique College, The Islamic University, Najaf, Iraq, Medical Laboratory Technique College, The Islamic University of Al Diwaniyah, Al Diwaniyah, Email: Iraqbaneen.j.jabil@jum.edu.iq
[6]MBBS; MPH, Columbia University, New York, United States, Email: drpranita95@gmail.com
[7]Student, Department of Pharmacy, University of Swabi, Pakistan, Email: rph.tufail@gmail.com
[8]Associate Professor, Department of Hematology, College of Medical Laboratory Sciences, University of Science and Technology, Omdurman, Sudan, Email: azad.88@hotmail.com
Corresponding Author : Tariq Rafique, Assistant Professor, Dadabhoy Institute of Higher Education, Karachi, Pakistan, Email: dr.tariq1106@gmail.com

Objective: To investigate awareness, familiarity and perceptions of targeted drug delivery systems in nanomedicine between demographic sub-groups. The objective of this research is to investigate how gender, education level and occupation affect attitudes towards nanomedicine with an emphasis on applications in oncology and others. Furthermore, the research explores some of the ethical issues connected to these new technologies.
Aim: The major aim of the study was to explore demographics associated with familiarization with nanomedicine, awareness regarding targeted drug delivery systems and perception towards effectiveness and safety. It also seeks to understand ethical questions and describes how these are situated among differing levels of perceptiveness and acquaintance.
Methodology: This cross-sectional study was conducted to measure the overall eHealth literacy scale among 200 participants through an online survey. Closed-ended and Likert scale questions

were used in the survey which sought information on demographics as well as awareness, familiarity with nanomedicine or perceptions of them. The data were analyzed using selected statistical tests: Chi-square, ANOVA, T-test and by a couple of tests (Spearman correlation), Mann-Whitney U test or Kruskal-Wallis H. These tests were employed to establish connections and differences in the variables under study.

Results: The Chi-square test showed no significant relation between gender and knowledge of targeted drug delivery systems (Chi2 = 0.981, p = 0.612). ANOVA test analysis on optimism about the future of nanomedicine versus different educational levels failed to show any significant difference type F = 0.147; p= 0.964). On a T-test analysis, awareness of the broader applications of nanomedicine and knowledge level was different two (T = -2.498, p = 0.013). The Spearman correlation between familiarity and effectiveness perceptions was weak, and non-significant (r = -0.111; p = 0.119). However, no differences were found for ethical concerns about nanomedicine in terms of hearing the term "targeted drug delivery systems" (U = 4941.0, p =.900 according to Mann-Whitney U test). The Kruskal Wallis H test discovered no significant interceptional variance concerning the number of challenges identified (H = 2.804, p =.591).

Practical Implications: This study clearly shows that the awareness and familiarity of people are crucial to its acceptance for use in a clinical setting. Engineering education programs aimed at a more accessible spectrum of nanomedicine applications, such as those beyond oncology, could also help bring public awareness and support for these technologies. Furthermore, with involvement of scientists from a wide range of areas also openly considering the ethical issues might go some way to restoring public trust and confidence in nanomedicine.

Importance: Examining the social and ethical aspects of nanomedicine adds importance to this study, as specific questions regarding familiarity with and awareness about targeted drug delivery systems have not been studied in different demographic groups. Further, it contributes fresh angles on the ethical landscape surrounding nanomedicine a topic that remains largely uncharted by Schaefer et al.

Conclusions: This study suggests that awareness is an important predictor of familiarity with nanomedicine, but not perception about the effectiveness and thus other factors i.e. trust in benefits vs ethical issues seem to be substantially evidenced by a greater predictive strength than awareness or support for development in making sense of this response disparity across countries/regions. This universal persistence of ethical challenges across tiers of awareness necessitates continued incisive dialogue and established principles to govern the safe deployment with the integrity of nanomedicine. The findings can greatly influence public health policy and clinical practice, highlighting the necessity of interdisciplinary strategies to overcome these barriers to boost nanomedicine utilization.

KEYWORDS: Nanomedicine; Targeted Drug Delivery; Awareness; Ethical Concerns; Oncology; Perceptions; Quantitative Analysis; Public Health Policy.

INTRODUCTION:

Over the years, nanomedicine, specifically designing targeted drug delivery systems, has attracted immense interest as it is foreseen to transform the treatment of diseases including cancer. The properties of nanoparticles (small size, extensive surface area-to-volume ratio) make them promising tools to help overcome the challenges described above and increase drug delivery precision. The patented technology is poised to overcome many of the failings associated with conventional therapies, including non-targeted drug delivery; systemic toxicity and an inability to effectively penetrate biological barriers. Given the increasing worldwide prevalence of chronic diseases such as cancer, new and potent non-toxic treatment options are urgently required highlighting not only the timeliness but also the importance of research into targeted drug delivery systems in nanomedicine (Hristova-Panusheva, Xenodochidis, Georgieva, & Krasteva, 2024).

It examines how targeted drug delivery systems in nanomedicine are understood and valued by certain population groups to contribute to the field of understanding what people think about biomedical innovations. From a salient view of technical developments and anticipated clinical benefits of these systems, substantially less attention has been given to how such technologies are perceived by the involved public, health care professionals (HCPs), or other stakeholders. Given that the effective uptake of new medical technology depends not just on its technical effectiveness but also upon user perceptions and acceptance, this would represent a substantial lacuna in the literature. These perceptions are important to know because, being the opinion of patients ultimately deciding whether or not they adhere to treatment regimens doctors proscribe and include nanomedicines into mainstream clinical practice (Gautam et al., 2024).

Additionally, the ethical consequences of nanomedicine when it comes to patient agreement and unintended effects cannot be overlooked in terms of these technologies taking off. Research on nanomedicine has indicated the importance of employing more robust ethical frameworks to direct and regulate its application since it is relatively new (and thus unpredictable in outcomes) compared with established therapeutic platforms (Timmermans & Berg 2010). Yet, there is little systematic enquiry into whether these ethical concerns are perceived differently by diverse demographic segments and the ramifications thereof on the overall adoption of nanomedicine in healthcare settings. These issues need to be resolved if the application of nanomedicine is not only ethical but also becomes socially acceptable (Chaudhari, Patel, & Kumar, 2024).

This study aims to examine the extent, knowledge and attitudes of nanomedicine-targeted drug delivery systems in a heterogeneous group of individuals. Focusing on both groups, divided according to different age brackets, sex differences as well as education and upbringing of a medical or non-medical person the study aims at giving broad insight into the possible relation between each of these factors on human attitudes towards nanomedicine. This work thus tries to overcome the limitations of existing literature by going beyond technical and clinical issues, obtaining also a dimension concerning social and ethical aspects is crucial for effective implementation in healthcare practice (Zhang, Chen, Hu, Zou, & Xu, 2024).

To further straddle the psychological and social aspects of this problem, wider variations in ethical concerns regarding nanomedicine will be investigated within groups. We are going to look at how much of a relation there is with the awareness of nanomedicine and then the level of concern for ethical issues behind it, if being more familiar correlates with anxieties. This makes this aspect of the research important especially for disclosure in informed consent, as would be required if patients are to participate in a nanomedicine clinical trial with relevant benefits and risks. This study addressed the following research questions: (1) How do various demographic characteristics influence awareness and familiarity with targeted drug delivery systems in nanomedicine? (2) How do different sociodemographic groups perceive the effectiveness and safety of these systems? • In what ways do concerns about ethics related to nanomedicine differ by level of awareness or familiarity (RQ 3)? 4) What Is The Clinical Relevance Of These Perceptions And Concerns To Nanomedicine Adoption And Integration? (Lammers, 2024).

The study also employed a quantitative research design to answer these two main questions with the perspective of a cross-sectional survey. This permits a single cross-sectional data collection from a large enough and diverse sample to assess current perceptions and attitudes towards nanomedicine. The survey includes both categorical (e.g. demographics) and ordinal data (eg level of agreement with statements about nanomedicine). Because of its structured and quantifiable nature, the Likert scale questions help us measure the attitudes on concerns among our respondents. The survey openings have ethically focused questions based on established bioethics literature, ensuring that the items measure constructs best captured by this type of renal issue. A sample of 200 respondents drawn from diverse demographic groups were part of the study. The sample is stratified by age, gender, education and occupation to enable consideration of how these factors impact public perceptions regarding nanomedicine. Analysis The data gathered from the questionnaire is processed utilizing descriptive statistics and inferential statistical tests such as Chi-square tests, and ANOVA´s T-test avenues that serve to detect trends in differences among subjects Profiling significant relationships among variables (Kuntawala & Hussain, 2024).

This paper is organized in the following way: In Section 2, we discuss the related work; the introduction provides context and background to this study, the research problem statement and objectives are described. After the introduction, a critical review of literature pertinent to nanomedicine and targeted drug delivery systems is conducted, helping to identify where existing research lacks within this domain while positioning their study into that gap. The methodologies contain the specific design of research, methods used for data collection and analytical tools that were employed during the study with enough detail to repeat researchers. The findings of the study are reported in the result section with complete tables and figures; no interpretation is given. The discussion corresponds with the research questions, results and highlights of related literature, discussing ramifications for future work as well as clinical implications. The conclusion finally summarizes the principal findings along with their significance, which will provide recommendations for both practitioners and researchers in nanomedicine (K.-N. Wang et al., 2024).

At mEpiLab, we have written this paper with the aim of building on a growing field within nanomedicine research that instead seeks to more fully engage and explore social and ethical concerns relating to targeted drug delivery systems. The study aims to explore the perspectives and concerns of diverse demographic groups, therefore generating content that can contribute to the development of strategies for enhancing nanomedicine adoption and acceptability among healthcare practices. The authors anticipate that their results will be important for the clinical deployment of nanomedicines as well as for a more general debate in medical ethics around emerging technologies (Puzzo, De Santo, Morelli, Leggio, & Pasqua, 2024).

LITERATURE REVIEW:

The targeted drug delivery systems in nanomedicine are one of the most awaited strategies for effective treatment, especially cancer. By increasing the dose delivered to specific sites, by providing better control over when and where the drug is released in bioactive form – all those systems designed for this type of cancer therapy use a nanotechnology approach -, these cultivation techniques can thereby improve therapeutic efficacy; Many tilt simultaneously

maximum exposure while minimizing side effects. The literature of nanomedicine and targeted drug delivery systems is voluminous in terms of existing research works about the development, therapeutic applications along potential bottlenecks. Nevertheless, there are remaining gaps in the literature that require further investigation such as perceptions, awareness and ethics of these technologies (J. Zhang et al., 2024).

Targeted drug delivery the idea that drugs can be designed to precisely distribute throughout disease cells while leaving healthy ones intact has been a hot topic in medicine since at least the late 1970s but applying this concept through nanotechnology provided new perspectives for its implementation on research and clinical settings. Among the first and most referenced investigations of this type is a study by Allen and Cullis that examined liposomal nanoparticles: nanomedicines comprised of lipid bilayers, which stabilized them as well as offering target-based drug delivery solutions. The studies published provided the scientific groundwork for the delivery of nanotechnology approaches including dendrimers, metal particles and quantum dots. This progress has greatly advanced the application of drug delivery at tumour sites, which improves therapeutic efficacy for oncology. While these early evaluations offered exciting possibilities, there was still more work to be done in examining long-term outcomes and the safety of the devices, further prompting a wave of research (Stilinski & Oluwaseyi, 2024).

After these classic studies, considerable work has been conducted around clinical translation or translational medicine (strategies and successes) specifically regarding nanomedicine for cancer applications. Nanotechnology has been introduced in cancer therapy for some years and it may be the optimal manner to improve physical statistical properties of materials mixed with anticancer activity en route to help reach efficient pharmacokinetic/biodistribution profiles as a drug carrier. The work of Ferrari and others highlights the potential for nanotechnology to address some drawbacks in chemotherapy such as non-specific distribution, and dose-limiting toxicity. The follow-up studies to those by Ferrari have shown that drug release with the assistance of nanoparticles can decrease tumour growth in preclinical models. For example, Wang et al. According to research, delivery of drugs via gold nanoparticles was successful for breast cancer cells and the size of tumour tissue decreased noticeably both compared with animals (Niikura et al. This and other studies demonstrate the promise of nanomedicine to combat these roadblocks in conventional cancer therapies, ultimately leading to improved patient outcomes (Shen, Pan, Gong, Gu, & Luo, 2024).

While several beaconing strategies have been developed over the years, this body of literature has also outlined significant hurdles to be overcome for these approaches to reach clinical applicability in targeted drug delivery systems within nanomedicine. Several challenges in scaling up nanoparticle production for clinical applications are the complexity of product stability due to rigid regulatory conditioning as well as manufacturing reproducibility. Also, the long-term safety and potential toxicity of nanoparticles have been another aspect about which different opinions exist accordingly some reviews have been discussed. For example, a study conducted by Nel et al. The possible cytotoxicity of some nanoparticles has been highlighted by Mahmoudi et al, and this makes the biocompatibility or biodistribution issues a concern to using these particles. Now, in light of the growing number of nanomedicine products being tested in clinical trials and marketed to consumers, these

questions are especially relevant. As nanomedicine further grows, it is essential to ensure a more complete assessment of its safety profile (Lv et al., 2024).

How nanomedicine is perceived is different from region to region, as well as between stakeholders involved with such research: the "ethical" implications of this new three-dimensional stakeholder map need further investigation and unpacking; one issue that has not received much attention so far concerns patient consent (or surrogate decision making) clinical trial regulations do no longer hold up once we become micros cope-like investigators on bodies using nano-medical devices; while it remains challenging to predict what adverse effects might be caused by these nano subdivisions. Each particle could undergo similar behaviour patterns within a person's body or tissue unit(s). Noting the complexity and limitless risks for clinical trials with nanomedicine, ethicists and researchers have criticized information provision as part of informed consent processes. As such, we need more stringent ethical standards and guidelines to guarantee that nanomedicine research subjects are provided with a comprehensive view of the risks and benefits associated. If patients are not informed of the dangers, where and in which respect the ethical requirements must be respected can reflect expectations as strong pressures for laser nano medications contributions, most prominent from a patient perspective. Still, a dearth of consensus in the extant literature on how best to incorporate informed consent into nanomedicine persists; thus far we see no systematic review has been conducted addressing this issue (Singh, 2024a).

Finally, the literature suggests that there is scant information on public awareness or perception of nanomedicine. Targeted drug delivery systems have been studied and developed in the areas of technical research, and clinical evaluation to a large extent; however, there are relatively few studies that investigate public and healthcare professionals' perspectives on these technologies. A study by Siegrist et al. According to a study by Barnes and Claw the attitude of the public is good toward nanotechnology, particularly where it relates to medical applications. Nonetheless, the survey concluded that this hopefulness remains subject to legitimate concerns over the possible hazards and moral issues associated with nanotechnology. This indicates that the perception of each stakeholder group about this issue might shape clinical uptake and use, which in turn emphasizes extended research to see if how each stakeholder perceives nanomedicine influences practical acceptance. According to Hsu et al, while the public's overall perspective on nanotechnology is still supportive, perceptions can vary dramatically based on application area with medical applications seen more favourably than non-medical domains like food or cosmetic use. These results suggest the importance of determining it in a wider context: both other nanotechnology applications and how plausible public perceptions are held, which needs further exploration (Pei et al., 2024).

This gap is particularly relevant considering the important role that public and professional perceptions always play when any new medical technologies are being adopted and implemented for use. The success of nanotechnologies in clinical practice, for example through the realization of nanomedicine, cannot be achieved simply by demonstrating technical efficacy and achieving regulatory approval: this must ultimately mean that health professionals are prepared to use these technologies, and patients are confident about their safety. This is highlighted through work on the adoption of technology which suggests that attitudes to perceived risk, trust and ethical considerations are pivotal for the uptake of new technologies. A study by Cacciatore et al. This is consistent with the work of Scheufele et al.

who emphasized that trust in scientists and regulatory agencies plays a key role in shaping public acceptance, which reinforces the importance of ensuring transparency and communication for establishing nanomedicine acceptance (Table 4). This underscores the importance of future research to investigate how such factors impact accepting and integrating nanomedicine in healthcare domains (He et al., 2024).

In addition, the current literature about targeted drug delivery systems is mainly concentrated on their design and clinical applications in oncology, whilst a few mentions are to be found for non-oncological therapeutic areas. Although treating cancer is a primary target for research in the field of nanomedicine, there has been an increasing desire to expand targeted drug delivery systems across non-oncology disorders such as cardiovascular and neurological diseases. A review by Silva et al. communicated that nanomedicine could drastically alter our approach towards cardiovascular disease treatment by allowing targeted drug delivery in atherosclerotic plaques and mitigating heart attacks or stroke risks. Likewise, nanomedicine has been researched for the treatment of neurological diseases in which it might help drugs to be administered through BBB (blood-brain barrier) a substantial difficulty in Alzheimer's disease and multiple sclerosis therapy methods (Sarella, Vegi, Vendi, Vipparthi, & Valluri, 2024).

Nanomedicine portends a wide future in medical fields beyond oncology yet there seems to be a disconnect in the literature between that promise and comparative analysis of these technologies across multiple medical fields. Most studies so far have been performed on nanomedicine in cancer therapy, while a limited number have been carried out in other areas. The finding indicates that further research is needed to investigate the greater potential of nanomedicine as well as its efficacy and safety in various therapeutic areas. Studies such as that of Shi et al., for instance, had established at the molecular level. Although Conde has advocated nanomedicine for application in the treatment of cardiovascular diseases, evidence to show how hospitalizations and cost-effectiveness compare these applications versus standard therapies is still needed (Wang, Gao, Feng, Mooney, & Mitragotri, 2024).

Moreover, the literature also highlights an absence of agreement on what putative good practices should be adopted for ethical and regulatory oversight. The high rate of technological innovation in this area has been such that the top developed systems have moved more quickly than their regulation, raising serious questions as to whether existing regulations are sufficient for governing nanomedicine. A study by Fadel et al. Relative to existing regulatory standards focused on substances, this novel insight stresses the importance of considering both nano-specific properties and unique features (e. g., size, surface area, reactivity), all biologically relevant when assessing NO release cytotoxicity; these characteristics may either underpin or forestall risk assessment scrutiny. Related metrics/targets for future development inclined to methods collectively superior to traditional one-dimensional form elements provide essential potential alignment for refinements in its use not solely down different target terabytes over metrics also layers mechanical companionship regime advances uniquely & misaligned BOX 2.). It also proposed that regulatory standards for nanomedicine be developed jointly between countries, rather than by individual territories, in recognition of the international nature of medical research and potential "offshore" clinical trials. The absence of uniform regulatory paradigms not only poses an uphill task for the researchers and developers but also instils fears regarding the

safety, effectiveness etc. of these nanomedicines when they reach the market (Walweel & Aydin, 2024).

The present study aims to bridge some of these gaps by examining the awareness, familiarity and perceptions about targeted drug delivery systems in nanomedicine across various demographic subsets. These differences in educational status, professional experience and exposure to medical technology will offer a range of perspectives on how these characteristics might contribute to an individual's perceptions of nanomedicines. That is crucial here, as perceptions and awareness drive the uptake of new medical technologies. An understanding of risk and benefit perception in different demographic groups has direct implications for the development of effective public communication strategies around nanomedicine. In addition, we also wish to contribute to the area of nanomedicine and ethics literature which concerns both healthcare professionals and the public at large (Dutta Chakraborty & Chakraborty, 2024).

METHODOLOGY:

The research presented in this article aimed to investigate relationships and differences between demographic factors, awareness, familiarity with TDDS-NM but also the perception of applications for different medical fields, especially oncology. This methodological approach was diligently arranged under the research onion framework, which contributed systematic direction throughout all stages of a study's implementation ensuring rigour and transparency. At the top or outermost layer of the research onion is your Research Philosophy in our case, it was grounded in positivism. The latter choice was undertaken because the purpose of this study is to quantify and analyze relationships among variables, just as it would be in a naturalistic inquiry. In this context, the concept of positivism was highlighted: it concerns itself with observable social facts and states that knowledge is to be gained from what can be observed or experienced, which justifies data collection through statistical observation for us to explain patterns. A positivist approach was selected to ensure that empirical data collection and analysis could be applied rigorously so that results are generalizable beyond the sample studied (Karami, Abdouss, & Maleki, 2024).

As we move to the core of research onion, this study adopted a deductive approach. Such a deductive design was appropriate since the study was directed at testing specific hypotheses about how demographic factors are related to perceptions regarding targeted drug delivery systems in nanomedicine. The deductive method is ideally suited for research that seeks to observe empirically existing theories or assumptions. These hypotheses were derived from the conclusions of theoretical models and literature developed before on nanomedicine & drug delivery systems. These hypotheses were then put into practice and the data gathered was analyzed to see if they indeed held in this research landscape. The research also employed a cross-sectional survey; thus, it was capable of collecting data at the same time from diverse samples (Bagade & Sampathi, 2024). (López-Estévez, Lapuhs, Pineiro-Alonso, & Alonso, 2024).

As this research will aim to capture a snapshot of the attitudes, perceptions and awareness levels within the population, it is best suited for cross-sectional design as this can facilitate identifying the same patterns or trends across various demographic groups. It is especially applicable in studies where the goal is to look at relationships or associations

between variables, rather than changes within a variable over time. Through capturing data at a single moment, the cross-sectional survey provided us with an opportunity to examine how different factors (gender, education and occupation) were influencing participants' perception of nanomedicine and targeted drug delivery systems. Equally important in the successful implementation of this study were the methodological decisions made when selecting CFS and HC sampling (Liu, Cheng, Liu, Hu, & Wen, 2024).

A purposive sampling strategy was used to select the sample as it allows an over-representation of specific characteristics to have, for example, individuals with varied backgrounds and levels of familiarity with medical technology and drug delivery systems. Purposive sampling or judgmental stratified is a non-probability technique in which the survey sample has been selected based on their subjects' characteristics i.e., another dimension of those characteristics such as age, sex etc. The sample for this study was a convenience sample of those 18 years and older, who would likely have ranged knowledge about nanomedicine. After data clean-up, we ended with a sample size of 200 respondents which was big enough to generate conclusive findings around the research questions. The sample was varied with men and women representing a range of age groups, educational capabilities, and professional sectors (Chen et al., 2024).

The gender split was almost 50/50 with male respondents making up 51% and female ones,49%. The balance was chosen deliberately to allow for the evaluation of whether there are any gender-related differences in perceptions. The split of the age distribution was this way 25% from 18–25 years, 27% between (26–35) years,20 %between(36-45)years,15%(46 to 55), and finally(Less than %)percentile were who are above56years and more One of the most important aspects of this study was that it could approach diversity around life stages in perceptions related to nanomedicine and targeted drug delivery systems. Another important socio-demographic variable in the sampling was education level. Diverse background in terms of education-related responses where, 30% responded as bachelor's degree holders, 25% was a master's degree completion and only by Doctorate obtaining personnel whereas the rest mix other form such as High School or some else (Nehal, Rohilla, Sartaj, Baboota, & Ali, 2024).

This difference in education was significant to study if educational level influenced knowledge and perception of nanomedicine. The sampling also had diversity in terms of professions: Medical (25%), Researcher (20%), Academician (15%), and Student/Other (combined 40%). Occupational diversity among the study participants offered insights into how professional orientation may determine perceptions of barriers and ethical concerns about targeted drug delivery systems (Pramanik, Gupta, Ghanwatkar, & Mahato, 2024).

The survey was distributed online, and featured questions requiring both categorical variables (i.e. selecting the degree to which a topic fits into pre-defined categories) and ordinal information for each of the research aims. The survey comprised different sections, the first section included questions about demographic profile i.e., age and sex of respondents educational level working status etc. The second part comprised questions regarding detection of targeted DDS, experience with nanomedicine, attitudes towards utilizing these approaches in oncology as well as concerns associated with the ethical aspects related to medical applications of nanoparticles. The survey included a mix of closed-ended questions (i.e. multiple-choice) and Likert scale-type questions, to explore beliefs that related directly to

research hypotheses but also the overall strength of diffusion theory on HDS adoption decisions SOSISCO et al (Khan, 2024).

The full survey was pretested with a small number of respondents before launch. Pretesting led to the removal of any question that may have caused ambiguity or influenced data quality, making this an important process for refining questions before establishing them throughout. The feedback from the pretest was utilized to modify question wording and structure where needed, which served to improve both survey instrument reliability and validity. The last survey was distributed online to give participants a chance to respond confidentially in their own time. The analysts employed analysis techniques specifically related to the data gathered and specific hypotheses tested. The data were analyzed by different statistical tests because each was appropriate to answer one or more of the research questions. The chi-square test of independence was used to see the relationship between gender, and subject-wise knowledge of targeted drug delivery systems. This test was especially helpful in determining if awareness levels depend on gender, and hence we got an answer that there is no significant association (Xie et al., 2024).

ANOVA test If you want to compare the average of ordinal numbers in more than 2 groups for example: comparing optimism about the future using no motivated statements related to nanomedicine among different levels of education. The ANOVA is a robust test for one-way group means analysis, and this study provided support that there are no significant relationships between education groups concerning optimism. The t-test was used to compare the means of two independent groups (i.e., whether familiarity with nanomedicine differed among those who were aware of other applications of nano and those who were not responsive). The best analysis is a t-test for comparing the means of two groups, and it suggests there was indeed a large difference meaning awareness corresponded with much more familiarity.

Spearman correlation tests were conducted to show the association between ordinal variables. Spearman's rank correlation is a non-parametric test used to determine the strength and direction of association between two ranked variables, thus where we are evaluating if better familiarity with nanomedicine tends to increase the perception of effectiveness (in this case, in oncology). The weak and nonsignificant correlation indicated that familiarity did not have a large impact on perceptions of effectiveness. For ordinal variables, the Mann-Whitney U test was used as a non-parametric test to compare the distribution between 2 independent groups. This portion of the test was used to compare levels of concern over ethical issues and whether or not respondents had previously heard about targeted drug delivery systems. There were no significant differences observed between the groups concerning ethical concerns (Russi, Marson, Laurini, & Pricl, 2024).

Ultimately, the Kruskal-Wallis H test compared ordinal variables across groups greater than two (i.e., whether respondents from different occupational backgrounds identified a similar number of challenges). Concerning the occupational groupings, however, there were no significant differences in the challenges identified when we applied a Kruskal-Wallis H test as an alternative method for ANOVA with data that do not satisfy parametric assumptions. Finally, this study was constructed with a testing method and an approach on purpose to make the results both strong invalidity as well as reliable. The research onion framework allowed the study to systematically focus on each layer within the range of layers germane to

advancing through a piece of work, from fundamental philosophical premises to analysis and collection of data. A cross-sectional survey design, purposive sampling procedures, and parametric and non-parametric statistical tests were used to analyze relationships of demographic factors with awareness familiarity & perceptions of targeted drug delivery systems in nanomedicine This detailed methodological approach allows for the reproducibility of this study by other researchers with similar interests in nanomedicine applications related to medical science (Subhan & Torchilin, 2024).

RESULTS:

In the present study, we aimed to investigate relationships between different sociodemographic attributes and perceptions of targeted drug delivery systems in nanomedicine ranging from oncology to other medical fields. A detailed statistical analysis was performed using a variety of tests to investigate these associations and differences across the respondent types. The outcomes are described as follows and will be supported with tables and figures to display the results effectively. First, a Chi-square test for independence was used to determine whether there is an association between gender and knowledge of applications other than oncology in the delivery systems mediated by targeted drugs. The resulting Chi2 and p-values of the test along with their corresponding values are displayed in Table 1. These results dwindle the association of gender with awareness, down to an insignificant level. Put differently, male and female respondents have a similar general awareness of the vast potential applications of nanomedicine. Figure 1 Bar chart: distribution of awareness levels by gender. This article, based on the test result would imply that gender does not matter when it comes to knowing more about targeted drug delivery systems in areas other than oncology (Krishna, Swathi, & Lakshmi, 2024).

Test Name	Metrics	p-value	Interpretation	Chi2 Values	Degrees of Freedom
Chi-square Test for Independence	Chi2 Value	0.612	No significant association between gender and awareness of applications beyond oncology.	0.980	2

Table 1: Chi-square Test for Independence



Figure 1: The bar chart displays the Chi2 value and the p-value from the Chi-square test

We then used ANOVA to test for the significance of differences in optimism about nanomedicine among respondents from different educational cohorts. ANOVA is a powerful statistical procedure that we can use to compare the means of multiple groups (in this case, different education levels) where it checks for statistically significant differences in their responses. As shown in Table 2, the F value of this analysis was 0.147 and p = 0.964. This supports the conclusion that the level of optimism towards each nanomedicine area within the different educational groups is not significantly different. Figure 2 graphically depicts this result, demonstrating that the level of optimism is uniform for educational groups. Taken together, this finding suggests that optimism regarding nanomedicine invocations is more or less widespread and not substantially affected by educational attainment (Singh, 2024b).

Test Name	**Metrics**	**p-value**	**Interpretation**	**F Value**
ANOVA Test	F Value	0.964	No significant differences in optimism about the future of nanomedicine	0.147

			across different education levels.	

Table 2: ANOVA Test



Figure 2: The ANOVA test graph shows the F value and the p-value

We conducted a T-test comparing the level of familiarity with nanomedicine between respondents aware that it went beyond oncology and those who were not. T-test is useful to compare the means of two groups (independent) and determine if they are statistically different from each other The results are shown in Table 3) and found a significant difference with T value -2.498, p=0.013 These results could mean that if one knows about the broader applications of nanomedicine, they are more likely to be familiar with this field rather than someone who does not know. Figure 3: Bar chart that communicates the same idea, again highlighting how much more or less familiar one group is over another. This p-value serves to demonstrate that if people are aware of the wider applications within nanomedicine they were significantly more likely to be knowledgeable about what ulterior many things can exist in terms of developments made (Nikandish, Wang, Bao, & Nikandish, 2024).

Test Name	**Metrics**	**p-value**	**Interpretation**	**T Values**

T-test	T Value	0.013	The a significant difference in familiarity with nanomedicine between those aware and unaware of applications beyond oncology.	-2.497

Table 3: T-test



Figure 3: The T-test graph highlights the T value and p-value

We also conducted a Spearman correlation test between vane-indicated knowledge level score and the effectiveness of targeted drug delivery systems in oncology. Spearman correlation: A Spearman rank-order r indicates the strength and direction of association between two ranked variables. As shown in Table 4, the correlation coefficient was −0.111 and the p-value was equal to 0.119 were found in this study. This observation suggests a weak

and statistically significant association between familiarity with nanomedicine features and the perception of its effectiveness in oncology. As shown in the corresponding figure (Figure 4) familiarity did not have a strong effect on how well respondents perceived these systems to function together. The non-significant p-value in our ANOVA did mean the case that familiarity and perceived effectiveness show little dependence on each other, which suggests there would be more factors than individual awareness of country branding to affect perceptual correctness (Agiba et al., 2024).

Test Name	**Metrics**	**p-value**	**Interpretation**	**Correlation Coefficient**
Spearman Correlation	Correlation Coefficient	0.118	Weak and non-significant correlation between familiarity with nanomedicine and perceived effectiveness of targeted drug delivery.	-0.110

Table 4: Spearman Correlation



Figure 4: The Spearman correlation graph illustrates the correlation coefficient and p-value

The Mann-Whitney U test was used to compare the two groups of ever-heard targeted drug delivery systems versus no, for levels of concern about ethical implications. Mann-Whitney U test. Table 5 shows the age of two groups A and B, to determine if there is a significant difference between them Mann-Whitney U-statistic =4941.0, p-value=0.900 Consequently, ethical concerns seem evenly distributed between cancer researchers and palliative care professionals. Figure 5 presents the corresponding bar chart where we can see using a different setting that indeed there seems to be no significant difference in how people felt and believed about their retaining ethical implications being equal while comparing Republicans vs Democrats. This suggests that awareness of targeted drug delivery systems did not affect the level of concern about their ethical implications, reflecting a plateau in which taxonomies are perceived as ethically constructible on an equal footing across all levels of public familiarity (Ghafari, Asefnejad, & Ogbemudia, 2024).

Test Name	**Metrics**	**p-value**	**Interpretation**	**U Statistic**
Mann-Whitney U Test	U Statistic	0.899	No significant difference in concern about ethical implications between those who have and those who have not heard of targeted drug delivery.	4941.0

Table 5: Mann-Whitney U Test



Figure 5: The Mann-Whitney U test graph presents the U statistic and p-value

The Kruskal-Wallis H test was then used to determine whether the number of perceived challenges in targeted drug delivery system development varied significantly among different professions. The Kruskal-Wallis H test is a nonparametric method to compare more than two groups on an ordinal variable. Table 6 shows the H larger value of 2.804 with an associated p-value equal to 591 and is generated from analysis as follows: This suggests that the significant difference will not have been predominantly due to some occupational groups identifying many more challenges than others. The corresponding figure (Figure 6) visually represents this, and hence shows a common distribution of challenges faced by the surveyed occupations. Therefore, it can be concluded that the public from all categories, no matter whether health care or pharmaceutical professionals, acknowledge almost the same number of problems in establishing and executing focused drug delivery methods for nano design (Drabczyk, Kudłacik-Kramarczyk, Jamroży, & Krzan, 2024).

Test Name	**Metrics**	**p-value**	**Interpretation**	**H Statistic**
Kruskal-Wallis H Test	H Statistic	0.591	No significant differences in the number of challenges identified across different occupations.	2.80

Table 6: Kruskal-Wallis H Test



Figure 6: The Kruskal-Wallis H test graph shows the H statistic and p-value

Taken together, the statistical analyses in this study shed newfound light on which demographic factors made a significant difference and how they related to differences or lack thereof that existed among perceptions of targeted DSS in nanomedicine. The findings of the

analysis underscore that these relationships are complex, and though awareness of applications which shape familiarity in nanomedicine could be paramount when considering factors such as gender and education levels also impact them. The data is put in perspective by the following, and more extensive literature tables (Ahmad et al., 2024).

DISCUSSION:

The findings of this study provide a broad picture of the targeted drug delivery system in nanomedicine in terms of awareness and familiarity along with perception as continued upon identifying the acceptance and ethical issues related to it. The results of the work complement and, in some cases, outperform the current state of knowledge on nanomedicine, discussing its advantages and possible difficulties in adapting to ordinary healthcare infrastructure. While discussing these outcomes, the relevance of the given findings must relate to the existing literature, the implications of such results have to be critically discussed, and the potential future developments in the mentioned field must be examined as well (Moradi Kashkooli, Hornsby, Kolios, & Tavakkoli, 2024).

Regarding the research questions, one of the most striking results of this study therefore concerns the fact that the results of the Chi-square test show no significative difference between the level of awareness of targeted drug delivery systems in nanomedicine depending on gender. This result points to the fact that female participants have a similar level of awareness about nanomedicine as male participants, which has been supported by earlier studies where awareness of emergent medical technologies is equally distributed among male and female populations. However, this finding also brings into question the other factors that make up awareness like educational information, and exposure to medical information which this study did not explore and should be investigated further. The lack of gender gap in awareness may therefore be attributed to the fact that nanomedicine campaigns, Ministries of Health and other education-related information dissemination on the use of nanotechnology have not biased their information by a gender relation or that both sexes have full access to the information (Coey, 2024).

The ANOVA test that was conducted in this study did not come up with any significant finding that indicated that there is any difference in the optimization of the future of nanomedicine amongst the different education level groups. This observation is somewhat surprising, given that the subject matter of nanomedicine is based on faith in the possibilities of new technologies, which do not appear to be limited to beneficiaries of formal schooling. This is quite opposed to some earlier studies that have used education level to posit that educated people are more optimistic about technology progress. The absence of substantial variability in this research could be related to the increased openness of the knowledge of nanomedicine due to the various media used in this study, making the information more readily available to individuals, and therefore increasing the level of optimism towards nanomedicine. This finding supports the need to develop and share information on nanomedicine with all people irrespective of their level of education (Wu, Wang, Anderson, & Tran, 2024).

The findings from the T-test where perceptions of familiarity with nanomedicine by the broader category and the detailed category were found to be significantly different are supported by the literature pointing to the fact that awareness is an influential factor in the

familiarity with new technologies as advanced by Rogers. Such work shows the necessity of further educational campaigns that would explain to people the various uses of nanomedicine, rather than only its application in the realm of cancer treatment, which people seem to be aware of to a significant extent. Extending the knowledge of the public to other possible fields of application, including cardiovascular and neurological diseases, it becomes possible, ultimately, to expand the general understanding of nanomedicine; as a result, it will be easier to accept and adapt into the clinical practice (Yan, Na, Liu, & Wu, 2024).

The low and insignificant values of the Spearman correlation coefficient that was used to establish the relationship between the level of familiarity with nanomedicine and the perceived effectiveness of the same in the treatment of cancer are another important finding that should be discussed further in this study. Although raising familiarity with technology tends to lead to more positive views about the effectiveness of the technology, no strong association in the current study implies that any other factors may be dominating views of the effectiveness of nanomedicine than familiarity. For example, the patient may trust the doctors and the healthcare system, have certain experience with cancer treatment of family members or friends, and receive positive or negative information about nanomedicine success or failure more often. This is in accord with the combined philosophy of this current study that shows that other factors come into play when technology is adopted and used besides easiness of handling. Further research should focus on these constructs and their effects in greater depth to recommend ways of enhancing the awareness of the public on nanomedicine (Mehta, Shah, Patel, Conte-Junior, & Joshi, 2024).

The lack of a significant difference in ethical concerns about nanomedicine among the participants who had heard about TDDS as compared to the participants who had not heard about it also indicates that ethical concerns about nanomedicine are steady regardless of TDDS awareness. This work makes more sense given the ongoing question as to the moral acceptability of nanomedicine. Although earlier research has pointed out that there can be ethical issues in the use and understanding of nanotechnology such as issues to do with informed consent and risks associated with the use of nanotechnology, the present research indicates that awareness does not necessarily remedy the likelihood of such issues arising. This might be due to weak ethical positions being more associated with the general tendencies in the perception of medical progress and technological solutions rather than specific information about nanomedicine. On the same note, it avails that ethical factors should act as the core concern when informing the public about nanomedicine, meaning that the concerns should be well handled and openly presented (Adetuyi & Vega, 2024).

Indeed, the Kruskal Walls H test revealing that there was no significant difference in the number of challenges reported in the development of targeted drug delivery systems across the different occupational groups goes further in supporting the generalization that the perceptions regarding nanomedicine are shared across a wide cross-section of the population. This gave a clear implication that the problems that are inherent in nanomedicine development and its deployment are appreciated not only by the medical fraternity but also by the researchers and educators. This claim is in line with the literature that regards challenges as one of the significant reasons why nanotechnology is poorly embraced in medicine; other barriers include stringently regulating production procedures, difficulties in scaling up production and toxicity. Thus, an understanding that the presence of these challenges is

recognized by people in various fields implies that the struggle against these barriers should be cross-disciplinary, in which scientists, healthcare workers, supervisory and legislative authorities, etc (Cho et al., 2024).

Altogether, these studies give a useful picture of the present state of knowledge, recognition, and attitudes to nanomedicine among people and different professions. It also reveals several gaps to be filled to get a better understanding of the factors that drive the adoption and acceptance of these technologies. For example, although this study found awareness and familiarity to be positively associated, it did not compare the kinds of information sources that underlie awareness. Future studies should explore the contribution of the various sources of information including the health facilities, educators, and media in enhancing the public awareness of nanomedicine. Besides, whereas this study provides an average perception of nanomedicine, the next study could investigate the differences in perception that exist depending on the nature of the application of the nanomedicine for example in cancer treatment as opposed to in treating cardiovascular diseases. Knowledge of such distinctions might reveal better ways of approaching the public and teaching them about the advances in nanomedicine and its application in various courses of therapy (Raval & Bhattacharya, 2024).

Closely related to sustainability, the ethical aspects of nanomedicine also deserve further exploration especially because ethical concerns have emerged repeatedly in this research. Thus, although the results do not indicate that ethical worries are magnified by awareness, they remind attention to these concerns in any exercise aimed at popularizing nanomedicine. Subsequent research may investigate how the ethical considerations differ from one culture to another and from one socioeconomic setting to another to determine if they affect patients' and clinicians' interest in nanomedicine. Also, it remains unclear how the world must prepare itself for safe nanotechnology applications as it calls for more extensive research into the creation of the ethical standards that might control the usage of nanomedicine in spheres where the consequences of these technologies work are yet unknown (Naser et al., 2024).

The practical consequences of these drug usage patterns for physicians and government healthcare initiatives are also profound. The level of trust regarding the possibilities that nanoparticles could bring to medicine combined with people's awareness of the difficult aspects of nanomedicine indicate that there is a clear interest in and understanding of, the need to spend more money on the practical application of this field. Nevertheless, the fact that there is a weak relationship between the levels of knowledge and perceived efficacy means that the processes aimed at the development of trust regarding nanomedicine need further elaboration. This could include attempting to more overtly discuss the costs and benefits of this kind of medical application as well as attempting to better 'enlist' the public, that is, get them to talk about what sort of values we want to see embodied in these new technologies (Manu et al., 2024).

From a policy perspective, the identification of impediments in different professional fields calls for the integration of multi-disciplinary in the implementation of the policies. It could also incorporate the establishment of a relationship between the regulatory systems and the innovation, that can easily adapt to the progress of nanotechnology, or the attempts towards the coordination of the nanomedicine production with proper standards of safety and

effectiveness. Some other recommendations that should also be implemented by the policymakers include explicating the part of public education in the offer diffusion of nanomedicine, making certain that the public gets adequate, suitable and precise information concerning the application of nanomedicine (Das, Chakraborty, Chakraborty, & Nath, 2024).

All in all, this study aims to report the findings of this cross-sectional survey concerning the awareness, familiarity, and attitude towards TDDSs in nanomedicine. The results show that awareness contributes to familiarity, the ethical similarity of the issues in each level of awareness, and the general acknowledgement of the issues in the development and application of nanomedicine. These findings can be deemed as having profound implications for the future of nanomedicines for both the clinical and the policy-making practice. Closing these gaps that are identified in this study, future research can help to contribute to the implementation of nanomedicine in the context of the health care provision to leverage its potential while avoiding the drawbacks (Caturano et al., 2024).

However, this work paradigm also highlights the constant debate needed among scientists, physicians, political decision-makers and society because of the numerous ethical, social and technical questions concerning nanomedicine. With the properly informed and engaged citizenry, and proper policies in place and devoted to the proper, conscious advancement of nanomedicine, we can guarantee that these technologies will indeed transform the face of medicine while remaining sensitive to the values of the society (Abujamous, Soltani, Al-Thawadi, & Agouni, 2024).

CONCLUSION:

The work presented in this study takes a closer look at the knowledge, awareness and perceptions of targeted nanomedicines for drug delivery among a diverse group of people. Keywords Accepted perception Ethical considerations Nanomedicine Quantitative analysis Statistical tests Anova, Chi-square, Mann Whitney U, Spearman, Significant T-test and H-tests. These results highlight the role of awareness in constructing an understanding of nanomedicine but suggest that ethical concerns are consistent across different levels of familiarity. In addition, the study demonstrates that there is a consensus as to why it will be difficult to produce and distribute technologies of this kind not only among professionals of different specialties.

One of the important findings is that gender has no statistically significant association with knowledge about nanomedicine-targeted drug delivery systems. Therefore, the knowledge about nanomedicine is quite evenly spread between both genders, implying that gender does not seem to mediate learning through these technologies. This point has important implications for how we communicate about nanomedicine, reminding us that outreach need not peak along gender lines and can be geared toward more general intermediate variables like information. In addition, optimism regarding the future of nanomedicine was not associated with differing levels of education attainment; meaning optimistic attitudes about the promise of nanomedicine are widespread and do not appear to have been constrained by more than requisite level formal training. The public is increasingly confident in these technologies' future, regardless of their education.

It also found that greater awareness of the broader application context for nanomedicine was correlated, in turn, with higher familiarity. Such findings are reported in

related literature where emphasis is placed on the role of awareness in fostering familiarity with new tools. Such a finding emphasizes the need for specific educational efforts targeted at improving public perceptions and understanding of nanomedicine in fields as varied as cardiovascular and neurological disease, not just cancer. If general awareness could be raised about nanomedicine, then increased knowledge of this area by the public would hopefully lead to greater degrees of acceptance and integration into clinical practice.

It is interesting to note that a weak, non-significant relationship emerged between familiarity with nanomedicine and perceptions about its effectiveness in oncology. This indicates that other variables such as trust in medical institutions, previous experience with cancer treatment and exposure to real-world information about the successes or failures of nanomedicine could explain more variance regarding whether people perceive nanomedicine as effective. Our results show that even if rewards are only used as an educational tool, they can be ineffective in influencing public perception of nanomedicine efficacy, suggesting familiarity with just the concept of nanomedicine may not change perceptions and trustworthiness must also be considered.

The uniform ethical worries regarding nanomedicine established at different levels of awareness emphasize the continuous and sustained necessity for future dialogue, input as well as invigoration by an improved moral groundwork. For this purpose, these frameworks will be used to direct the responsible application of nanomedicine as a technology for which long-range effects are less known. Not only is the ethics of nanomedicine crucial for patient protection, but it also provides one of the key conditions for gaining public trust in these advancing technologies.

There seems to be considerable consensus that the development and deployment of nanomedicine faces not only multiple but also multilevel constraints, as acknowledged by writers in disciplines including professional medical writing. These widespread perceptions suggest a demand for both more concerted and interdisciplinary responses to traverse these barriers. This roadmap involves establishing more flexible regulation frameworks, standardizing production processes and extensive testing of safety. Collectively, the challenges outlined in this patent series demonstrate that only through multidisciplinary collaboration amongst researchers and healthcare providers will nanomedicine be unlocked to its full potential safely and effectively for patients.

This study, therefore, contributes to the burgeoning global literature on nanomedicine by comprehensively exploring determinants of awareness & familiarity and perceptions about targeted drug delivery systems. Findings highlight roles for awareness in determining familiarity, consistent ethical worries irrespective of the level of understanding and broad concern regarding challenges to the production/implementation phases related to nanomedicines. The paper, published as a letter to the editor in Nature Nanotechnology, 1 could have wide-ranging impacts on nanomedicine strategies both from clinical and public health perspectives.

Future research to fill these gaps can help integrate nanomedicine into healthcare more responsibly and effectively, thus helping maximize its benefits relative to the potential risks. The study also underscores the necessity of continuous vibrant dialogue between scientists, practitioners from healthcare system regulatory bodies and governmental agencies as well as civil society to address multifaceted ethical, societal and technical challenges in

nanomedicine. Through improved public engagement and information, along with responsible policymaking that promotes the safe progress of nanomedicine technologies we can guarantee these advances contribute to a changing health organization world but also enhance societal values.

REFERENCES:

1. Abujamous, L., Soltani, A., Al-Thawadi, H., & Agouni, A. (2024). Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer. Biomolecules and Biomedicine, 24(2), 230.
2. Adetuyi, B. O., & Vega, L. (2024). Advancements in Nanocarrier-Mediated Drug Delivery: Precision Strategies for Targeted Therapeutics and Improved Treatment Outcomes: Springer.
3. Agiba, A. M., Elsayyad, N., ElShagea, H. N., Metwalli, M. A., Mahmoudsalehi, A. O., Beigi-Boroujeni, S., . . . Segura-Medina, P. (2024). Advances in Light-Responsive Smart Multifunctional Nanofibers: Implications for Targeted Drug Delivery and Cancer Therapy. Pharmaceutics, 16(8), 1017.
4. Ahmad, J., Ahamad, J., Algahtani, M. S., Garg, A., Shahzad, N., Ahmad, M. Z., & Imam, S. S. (2024). Nanotechnology-mediated delivery of resveratrol as a promising strategy to improve therapeutic efficacy in triple-negative breast cancer (TNBC): Progress and promises. Expert Opinion on Drug Delivery, 21(2), 229-244.
5. Bagade, O., & Sampathi, S. (2024). Restoration and Sustenance of Nano Drug Delivery Systems: Potential, Challenges, and Limitations Biosystems, Biomedical & Drug Delivery Systems: Characterization, Restoration and Optimization (pp. 105-139): Springer.
6. Caturano, A., Nilo, R., Nilo, D., Russo, V., Santonastaso, E., Galiero, R., . . . Marfella, R. (2024). Advances in Nanomedicine for Precision Insulin Delivery. Pharmaceuticals, 17(7), 945.
7. Chaudhari, R., Patel, V., & Kumar, A. (2024). Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies. Nanoscale Advances.
8. Chen, J., Hu, S., Sun, M., Shi, J., Zhang, H., Yu, H., & Yang, Z. (2024). Recent advances and clinical translation of liposomal delivery systems in cancer therapy. European Journal of Pharmaceutical Sciences, 106688.
9. Cho, H., Huh, K. M., Shim, M. S., Cho, Y. Y., Lee, J. Y., Lee, H. S., & Kang, H. C. (2024). Beyond Nanoparticle-Based Intracellular Drug Delivery: Cytosol/Organelle-Targeted Drug Release and Therapeutic Synergism. Macromolecular Bioscience, 2300590.
10. Coey, T. (2024). Nanomedicine in Oncology: A Critical Review on Epidemiology, Health Impacts, Challenges, and Future Outlook. Progress in Drug Discovery & Biomedical Science, 7(1).
11. Das, S., Chakraborty, P., Chakraborty, D. D., & Nath, L. K. (2024). Advancements in Nanoengineered Paclitaxel Formulations: A Comprehensive Review of Blood-Brain Barrier Infiltration Strategies for Glioblastoma Therapy. Biomedical Engineering Advances, 100122.
12. Drabczyk, A., Kudłacik-Kramarczyk, S., Jamroży, M., & Krzan, M. (2024). Biomaterials in Drug Delivery: Advancements in Cancer and Diverse Therapies. International Journal of Molecular Sciences, 25(6), 3126.
13. Dutta Chakraborty, D., & Chakraborty, P. (2024). Cancer-specific Nanomedicine Delivery Systems and the Role of the Tumour Microenvironment: A Critical Linkage. Current Nanomedicine (Formerly: Recent Patents on Nanomedicine), 14(2), 115-126.
14. Gautam, R., Mittal, P., Goyal, R., Dua, K., Mishra, D. K., Sharma, S., & Singla, R. K. (2024). Nanomedicine: Innovative Strategies and Recent Advances in Targeted Cancer Therapy. Current Medicinal Chemistry.

15. Ghafari, Y., Asefnejad, A., & Ogbemudia, D. O. (2024). Gold Nanoparticles in Biomedicine: Advancements in Cancer Therapy, Drug Delivery, Diagnostics, and Tissue Regeneration. Scientific Hypotheses, 1(1).
16. He, K., Chen, M., Liu, J., Du, S., Ren, C., & Zhang, J. (2024). Nanomedicine for cancer targeted therapy with autophagy regulation. Frontiers in Immunology, 14, 1238827.
17. Hristova-Panusheva, K., Xenodochidis, C., Georgieva, M., & Krasteva, N. (2024). Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology. Pharmaceuticals, 17(6), 677.
18. Karami, M. H., Abdouss, M., & Maleki, B. (2024). The state of the art metal nanoparticles in drug delivery systems: A comprehensive review. Nanomedicine Journal, 11(3).
19. Khan, M. (2024). Nanoparticle-Mediated Cancer Chemotherapy Personalized and Precision Nanomedicine for Cancer Treatment (pp. 183-216): Springer.
20. Krishna, V. J., Swathi, L., & Lakshmi, S. S. (2024). Integrating Immunotherapy and Nanotechnology in Advanced Drug Delivery Systems for Precision Cancer Therapy. Journal of Clinical and Pharmaceutical Research.
21. Kuntawala, D. H., & Hussain, Z. U. N. M. (2024). Significance of Nano-drug Delivery in Cancer Therapy, Application of Nanoparticles in Overcoming Drug Resistance, Targeted Therapy, and Immunotherapy Nano Drug Delivery for Cancer Therapy: Principles and Practices (pp. 1-24): Springer.
22. Lammers, T. (2024). Nanomedicine tumour targeting. Advanced Materials, 2312169.
23. Liu, X., Cheng, Y., Liu, Y., Hu, X., & Wen, T. (2024). Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview. Frontiers in Immunology, 15, 1328145.
24. López-Estévez, A. M., Lapuhs, P., Pineiro-Alonso, L., & Alonso, M. J. (2024). Personalized cancer nanomedicine: Overcoming biological barriers for intracellular delivery of biopharmaceuticals. Advanced Materials, 36(14), 2309355.
25. Lv, Y., Li, W., Liao, W., Jiang, H., Liu, Y., Cao, J., . . . Feng, Y. (2024). Nano-drug delivery systems based on natural products. International Journal of Nanomedicine, 541-569.
26. Manu, K., Kaur, G., Kar, A., Giri, L., Almalki, W. H., Gupta, N., . . . Dandela, R. (2024). The prospect of nano-based drug delivery approaches against pancreatic cancer and expected pitfalls of the technology Recent Advances in Nanocarriers for Pancreatic Cancer Therapy (pp. 419-442): Elsevier.
27. Mehta, S., Shah, V., Patel, G., Conte-Junior, C. A., & Joshi, N. (2024). A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC). Journal of Nanoparticle Research, 26(5), 1-54.
28. Moradi Kashkooli, F., Hornsby, T. K., Kolios, M. C., & Tavakkoli, J. (2024). Ultrasound-mediated nano-sized drug delivery systems for cancer treatment: Multi-scale and multi-physics computational modelling. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 16(1), e1913.
29. Naser, I. H., Zaid, M., Ali, E., Jabar, H. I., Mustafa, A. N., Alubiady, M. H. S., . . . Jalal, S. S. (2024). Unveiling innovative therapeutic strategies and future trajectories on stimuli-responsive drug delivery systems for targeted treatment of breast carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(6), 3747-3770.
30. Nehal, N., Rohilla, A., Sartaj, A., Baboota, S., & Ali, J. (2024). Folic Acid Modified Precision Nanocarriers: Charting New Frontiers in Breast Cancer Management Beyond Conventional Therapies. Journal of Drug Targeting(just-accepted), 1-33.
31. Nikandish, M., Wang, H., Bao, X., & Nikandish, M. (2024). Enhancing Drug Delivery Precision: Development and Optimization of Nanoparticle-Based Formulations for Targeted Therapy in Preclinical Models. ESI Preprints, 26, 232-232.

32. Pei, J., Yan, Y., Jayaraman, S., Rajagopal, P., Natarajan, P. M., Umapathy, V. R., . . . Thalamati, D. (2024). A review on advancements in the application of starch-based nanomaterials in biomedicine: Precision drug delivery and cancer therapy. International Journal of Biological Macromolecules, 130746.
33. Pramanik, N., Gupta, A., Ghanwatkar, Y., & Mahato, R. I. (2024). Recent advances in drug delivery and targeting for the treatment of pancreatic cancer. Journal of Controlled Release, 366, 231-260.
34. Puzzo, M., De Santo, M., Morelli, C., Leggio, A., & Pasqua, L. (2024). The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi-Targeting Drugs Through Materials Engineering: A Possible Future Scenario. Small Science, 2400113.
35. Raval, H., & Bhattacharya, S. (2024). Exploring the Potentials of Hyaluronic Acid-coated Polymeric Nanoparticles in Enhanced Cancer Treatment by Precision Drug Delivery, Tackling Drug Resistance, and Reshaping the Tumour Micro Environment. Current Medicinal Chemistry.
36. Russi, M., Marson, D., Laurini, E., & Pricl, S. (2024). Targeted drug delivery: concepts, approaches, and applications Novel Formulations and Future Trends (pp. 223-265): Elsevier.
37. Sarella, P. N. K., Vegi, S., Vendi, V. K., Vipparthi, A. K., & Valluri, S. (2024). A Promising Frontier in Nanotechnology-based Drug Delivery. Asian Journal of Pharmaceutical Research, 14(2).
38. Shen, X., Pan, D., Gong, Q., Gu, Z., & Luo, K. (2024). Enhancing drug penetration in solid tumours via nanomedicine: Evaluation models, strategies and perspectives. Bioactive Materials, 32, 445-472.
39. Singh, D. (2024a). Beyond the Maze: Recent Advancements in Molecular and Cellular Tethered Drug Delivery Systems. ASSAY and Drug Development Technologies.
40. Singh, D. (2024b). A sojourn on mitochondria-targeted drug delivery systems for cancer: Strategies, clinical and prospects. Mitochondrion, 74, 101826.
41. Stilinski, D., & Oluwaseyi, J. (2024). Nanomedicine and Drug Delivery: Enhancing Treatment Efficacy and Precision with Nanotechnology.
42. Subhan, M. A., & Torchilin, V. P. (2024). Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy. Bioengineering, 11(8), 830.
43. Walweel, N., & Aydin, O. (2024). Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies. ACS omega, 9(26), 27832-27852.
44. Wang, K.-N., Zhou, K., Zhong, N.-N., Cao, L.-M., Li, Z.-Z., Xiao, Y., . . . Liu, B. (2024). Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety. Life Sciences, 122635.
45. Wang, L. L.-W., Gao, Y., Feng, Z., Mooney, D. J., & Mitragotri, S. (2024). Designing drug delivery systems for cell therapy. Nature Reviews Bioengineering, 1-16.
46. Wu, K. Y., Wang, X. C., Anderson, M., & Tran, S. D. (2024). Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma. Molecules, 29(10), 2263.
47. Xie, L., Xie, D., Du, Z., Xue, S., Wang, K., Yu, X., . . . Fang, C. (2024). A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer. International Journal of Oncology, 64(4), 1-16.
48. Yan, S., Na, J., Liu, X., & Wu, P. (2024). Different Targeting Ligands-Mediated Drug Delivery Systems for Tumour Therapy. Pharmaceutics, 16(2), 248.
49. Zhang, J., Li, Y., Guo, S., Zhang, W., Fang, B., & Wang, S. (2024). Moving beyond traditional therapies: the role of nanomedicines in lung cancer. Frontiers in Pharmacology, 15, 1363346.
50. Zhang, Y., Chen, X., Hu, B., Zou, B., & Xu, Y. (2024). Advancements in nanomedicine delivery systems: unravelling immune regulation strategies for tumour immunotherapy. Nanomedicine, 1-20.